Emergent BioSolutions (EBS) Total Current Liabilities (2010 - 2026)

Emergent BioSolutions' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $148.7 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 32.89% year-over-year to $148.7 million; the TTM figure through Mar 2026 stood at $148.7 million (up 32.89% YoY), while the FY2025 annual figure was $132.2 million, down 18.6% from the prior year.
• Total Current Liabilities was $148.7 million for Q1 2026 at Emergent BioSolutions, up from $132.2 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $1.2 billion in Q4 2022 to a low of $111.9 million in Q1 2025.
• Historically, Total Current Liabilities has averaged $443.6 million across 5 years, with a median of $264.4 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities soared 387.84% in 2023, then sank 82.24% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $1.2 billion in 2022, then sank by 47.0% to $651.3 million in 2023, then slumped by 75.07% to $162.4 million in 2024, then fell by 18.6% to $132.2 million in 2025, then grew by 12.48% to $148.7 million in 2026.
• The last three Total Current Liabilities figures came in at $148.7 million (Q1 2026), $132.2 million (Q4 2025), and $136.5 million (Q3 2025), per Business Quant data.